Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dalcetrapib - DalCor Pharmaceuticals

Drug Profile

Dalcetrapib - DalCor Pharmaceuticals

Alternative Names: JTT-705; R 1658; RG1658; RO 4607381

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Japan Tobacco
  • Developer DalCor Pharmaceuticals; Japan Tobacco; Montreal Heart Institute; Roche
  • Class Antihyperlipidaemics; Cyclohexanes; Small molecules; Thioesters
  • Mechanism of Action Cholesterol ester transfer protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute coronary syndromes
  • Discontinued Atherosclerosis; Coronary disorders; Hyperlipidaemia

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 18 Jul 2016 Pharmacodynamics data from the phase III dal-OUTCOMES trial in Acute coronary syndromes released by DalCor Pharmaceuticals
  • 26 Apr 2016 Phase-III clinical trials in Acute coronary syndromes in Canada (PO) (NCT02525939)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top